Organisation paid for research Program year 2025 Source: CMS Open Payments

Chemidox Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$5,074,609

289 payments

Through program year 2025, Chemidox Clinical Trials Inc is reported as receiving $5,074,609 in research payments, across 289 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $157,874 35
2024 Research $165,810 20
2023 Research $475,987 63
2022 Research $1,715,331 89
2021 Research $2,549,907 81
2020 Research $9,700 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Pfizer Inc. $4,179,285 193 payments
  2. Eli Lilly and Company $604,991 7 payments
  3. Sumitomo Pharma America, Inc. $111,384 34 payments
  4. Bavarian Nordic A/S $66,091 34 payments
  5. Myovant Sciences GmbH $62,096 18 payments
  6. AxoGen $50,763 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 23 Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Sarscov2 Rna Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Pregnant Women 18 Years of Age and Older $2,178,315 54 payments
  2. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $846,422 48 payments
  3. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $760,650 50 payments
  4. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $389,676 3 payments
  5. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $326,322 34 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $212,616 3 payments
  7. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $67,575 7 payments
  8. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $53,522 12 payments
  9. Study of Axoguard Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE) $50,763 3 payments
  10. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $46,125 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record